Pascal Furet

Research.com Recognitions

• 2023 - Research.com Biology and Biochemistry in Switzerland Leader Award

Overview

Best Publications

• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  Sauveur-Michel Maira;Frédéric Stauffer;Josef Brueggen;Pascal Furet

  1660
  Citations

• In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

  Carlos Garcia-Echeverria;Mark Andrew Pearson;Andreas Marti;Thomas Meyer

  662
  Citations

• Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

  Vito Guagnano;Pascal Furet;Carsten Spanka;Vincent Bordas

  622
  Citations

• The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

  Andrew A. Wylie;Joseph Schoepfer;Wolfgang Jahnke;Sandra W. Cowan-Jacob

  501
  Citations

• Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

  Lipika Goyal;Supriya K. Saha;Leah Y. Liu;Giulia Siravegna

  488
  Citations

• Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

  Christine Fritsch;Alan Huang;Christian Chatenay-Rivauday;Christian Schnell

  482
  Citations

• Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors

  Peter Traxler;Pascal Furet

  476
  Citations

• Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

  Doriano Fabbro;Stephan Ruetz;Elisabeth Buchdunger;Sandra W Cowan-Jacob

  450
  Citations

• Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

  Pascal Furet;Vito Guagnano;Robin A. Fairhurst;Patricia Imbach-Weese

  444
  Citations

• Inhibitors of tyrosine kinases

  Werner Breitenstein;Pascal Furet;Sandra Jacob;Paul William Manley

  438
  Citations

• Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

  J. Schoepfer;W. Jahnke;G. Berellini;S. Buonamici

  437
  Citations

• Tyrosine kinase inhibitors: From rational design to clinical trials

  Peter Traxler;Guido Bold;Elisabeth Buchdunger;Giorgio Caravatti

  431
  Citations

• Nye Imidazokinoliner, fremgangsmåter for fremstilling av slike og farmasøytiske preparater inneholdende slike, samt anvendelse som et farmasøytiske preparat og anvendelse for fremstilling av et farmasøytisk preparat.

  Furet Pascal;Garcia-Echeverria Carlos;Stauffer Frédéric

  386
  Citations

• Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases

  Andreas Floersheimer;Pascal Furet;Paul William Manley;Guido Bold

  377
  Citations

• Different susceptibility of protein kinases to staurosporine inhibition Kinetic studies and molecular bases for the resistance of protein kinase CK2

  Flavio Meggio;Arianna Donella Deana;Maria Ruzzene;Anna M. Brunati

  366
  Citations

• Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

  Carlos García-Echeverría;Patrick Chène;Marcel J. J. Blommers;Pascal Furet

  324
  Citations

• New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

  Bold G;Altmann Kh;Frei J;Lang M

  322
  Citations

• Imatinib: a selective tyrosine kinase inhibitor.

  P.W. Manley;S.W. Cowan-Jacob;E. Buchdunger;D. Fabbro

  317
  Citations

• Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

  Peter Traxler;Guido Bold;Joerg Frei;Marc Lang

  313
  Citations

• Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.

  Sandra W. Cowan-Jacob;Gabriele Fendrich;Andreas Floersheimer;Pascal Furet

  311
  Citations